ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, will be presenting at the inaugural BTIG Emerging Technologies in Healthcare Diagnostics symposium. Richard Montagna, Ph.D., senior vice president for Scientific and Clinical Affairs at Rheonix, will speak about genomic workflow innovation and discuss the company’s breakthrough innovation utilizing a proprietary liquid-liquid extraction methodology for automated preparation of paraffin-preserved tissue samples for nucleic acid analysis.
Dr. Montagna’s comments will illustrate how the company incorporates patent 8,852,919, “Microfluidic Apparatus, Method, and Applications,” into its Rheonix CARD® cartridge, which is operated using its automated instrument, the EncompassMDx™. The patented method will help researchers, clinicians and scientists analyze the enormous backlog of tissue samples preserved in paraffin. Rheonix has demonstrated that the paraffin extraction method produces excellent results in preparing samples for next-generation sequencing library preparation and traditional nucleic acid analysis of the processed tissues.
“The ’919 patent is truly a game-changing achievement that provides further validation of the Rheonix CARD system. More importantly, it will serve to increase the rate of adoption for NGS instruments throughout the healthcare spectrum of reference and specialty laboratories, major university research and medical systems, to hospitals in communities everywhere, by removing the front-end bottleneck in NGS library preparation. I look forward to speaking at the BTIG conference about our capabilities,” said Montagna.
Montagna has more than 30 years of leadership experience and has managed the commercialization of more than 40 biotechnology products. He has published 40 scientific papers and holds a number of patents in the biosensor area. Montagna is also an adjunct professor in the department of biological and environmental engineering at Cornell University.
The EncompassMDx is a platform with unmatched versatility and affordability that performs fully automated, complex molecular assays in an easy-to-use and economical format using the Rheonix CARD cartridge. The CARD is a cartridge the size of a smartphone that can run several biological samples through a fully integrated molecular analysis with no user intervention—it automatically manipulates the network of microfluidic pumps, valves and channels. The EncompassMDx has the ability to dramatically decrease the cost of testing, while increasing user efficiency and accuracy. Furthermore, the product’s automation, capability for high throughput and high complexity, and unique sample-to-result system will allow the platform to solve workflow inefficiencies within the diagnostic segment of the health care industry.
The BTIG Emerging Technologies in Healthcare Diagnostics symposium will be held Sept. 29-30 at The Benjamin in New York City. Leading diagnostic companies will present on a series of thematic panels to familiarize attendees with the diagnostic space and associated technologies.
For more information, visit www.rheonix.com.
About Rheonix:
Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the EncompassMDx™ platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and EncompassMDx family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit www.rheonix.com.
# # #
Patti Gomez
pgomez@pinckneyhugo.com
315-476-6700
Help employers find you! Check out all the jobs and post your resume.
